Premium
P4‐383: Tarenflurbil (MPC‐7869), a selective Aβ42‐lowering agent, has no significant effect on the pharmacokinetics and pharmacodynamics of warfarin
Author(s) -
Mather Gary,
Harrison Shuree,
Woodland Deane,
Swabb Edward
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.2453
Subject(s) - warfarin , pharmacokinetics , medicine , tolerability , pharmacodynamics , pharmacology , prothrombin time , crossover study , partial thromboplastin time , population , therapeutic index , cyp2c9 , cmax , anesthesia , drug , placebo , adverse effect , coagulation , atrial fibrillation , alternative medicine , environmental health , pathology , cytochrome p450 , metabolism